Investors

The hard work of building businesses is what drives returns for investors, but maximising value also means buying well and selling well. As your advisers, we can make a big difference to the outcome.

Our deep sector knowledge and long-established international network mean we can offer insights on industry trends, strategic positioning and competitive intelligence that give us an edge over generalist advisers. This specialism is allied to buy-side and sell-side M&A expertise across the full range of deal structures – from growth capital to minority stake sales, buy-outs and strategic exits.

Whether you are a venture capital provider, buyout fund, family office or infrastructure investor, we understand your objectives and have the capability to help you achieve them.

Crucially, we work together as one-team. We collaborate and work with partners, and our carefully nurtured internal culture permeates through the whole organisation. As Managing Partner, Julie Langley puts it, “For Results, every deal is important to everybody in our firm.”

Deals are incredibly complex and never straightforward, but we never give up once we are on board. 100 per cent of the deals we’ve closed are referenceable from our past clients.

Mark Williams

Partner

Services

We’ve been providing independent M&A and corporate finance advice and execution services to entrepreneurs, corporates and investors in the technology and healthcare sectors for over 30 years. Whether your aim is to realise value or to find a partner for future growth, we will be your guide.

M&A

When the time comes, we’re by your side every step of the way. We help you evaluate your market, find the right buyer, and deliver the true value of your business.

Divestments

With a strong track record in company carve-outs, we can help you realign your portfolio and redeploy capital to the growth of your core business.

Licensing

We support clients with in-licensing, out-licensing, drug licensing, and facility licensing and we understand the complexities that are unique to licensing deals.

Equity Fundraising

We understand that optimising terms is critical, but so is finding the right partner for growth. We help articulate your equity story, target the best investors and negotiate the right deal.

Strategic Advice

Having completed over 300 transactions, we bring the breadth of perspectives and depth of business experience to provide advice on strategic options for businesses.

Recent Deals

Aug 2021
has merged with
a Vespa Capital-backed company
Aug 2021
has been acquired by
an Odyssey Investment Partners-backed company
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
has acquired
Jul 2021
has received investment from
Jun 2021
has been acquired by
May 2021
has been acquired by
a Behrman Capital-backed company
May 2021
has formed a strategic alliance with
Apr 2021
has invested in

Results. Great people creating great outcomes, together.

Latest Insights

Reports
21st July 2021

Marketing Services: Global M&A and Public Company Performance H1 2021

We are pleased to share with you the H1 2021 Marketing Services Sector Review, where we analyse global M&A activity and public market performance in the marketing services sector. We continue to see very good levels of deal activity in the Marketing Services sector with H1 2021 deal volume up by 22% on H1 2020 […]

Reports
19th July 2021

The Global Technology Market Review – Q2 2021

As we predicted in Q1, deal activity has continued to increase in Q2 and the technology market remains very strong for M&A and public trading and optimism for future growth remains very healthy across all the technology sectors we track. M&A continues to be driven by strong levels of investment by private equity (directly and […]

Insights
17th May 2021

The next chapter: Changing market dynamics in commercialisation and medical communications

The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw medcomms groups play a crucial part in keeping pharma companies connected with patients and healthcare professionals, and dealmaking was frenetic on both sides of the Atlantic, for smaller agencies as well as for emerging ‘CCOs’. […]